Korean Diabetes J.  2008 Feb;32(1):7-9. 10.4093/kdj.2008.32.1.7.

Diabetic Nephropathy - Preventive effects of lithospermic acid B (LAB)

• Hong EG

• KMID: 2298104
• DOI: http://doi.org/10.4093/kdj.2008.32.1.7

Abstract

No abstract available.

MeSH Terms

Benzofurans
Depsides
Diabetic Nephropathies
Benzofurans
Depsides

Reference

1. Ziyadeh FN. Renal tubular basement membrane and collagen type IV in diabetes mellitus. Kidney Int. 1993. 43:114–120.

2. Ziyadeh FN, Goldfarb S. The renal tubulointerstitium in diabetes melltus. Kidney Int. 1991. 39:464–475.

3. Ziyadeh FN. The extracellular matrix in diabetic nephropathy. Am Kidney Dis. 1993. 22:736–744.

4. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993. 329:977–986.

5. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998. 352:837–853.

6. Ziyadeh FN. Mediators of diabetic renal disease: The case for TGF-beta as the major mediator. J Am Soc Nephrol. 2004. 15:Suppl. 1. S55–S57.

7. Brosius FC 3rd. Trophic factors and cytokines in early diabetic glomerulopathy. Exp Diabesity Res. 2003. 4:225–233.

8. Whiteside CI, Thompson J. The role of angiotensin-II in progressive diabetic glomerulopathy in the rat. Endocrinology. 1989. 125:1932–1940.

9. Senger DR, Van Der Water L, Brown LF, Nagy JA, Yeo KT, Yeo TK, Berse B, Jackson RW, Dvorak AM. Vascular permeability factor in tumor biology. Cancer and Metastasis Rev. 1993. 12:303–324.

10. Iijima K, Yoshikawa N, Connolly DT, Nakamura H. Human mesangial cells and peripheral blood mononuclear cells produce vascular permeability factor. Kidney Int. 1993. 44:959–966.

11. Sharma K, Ziyadeh FN. The emerging role of transforming growth factor-β in kidney diseases. Am J Physiol. 1994. 35:F829–F842.

12. Mogensen CE, Keane WF, Bennett PH, Jerums G, Parving HH, Passa P, Steffes MW, Striker GE, Viberti GC. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet. 1995. 346:1080–1084.

13. Gilbert RE, Tsalamandris C, Bach LA, Goodall I, Young V, Seeman E, Murray RM. Glycemic control and the rate of progression of early diabetic kidney disease: a nine year longitudinal study. Kidney Int. 1993. 44:855–859.

14. Mogensen CE. Progression of nephropathy in long-term diabetic with proteinuria and effect of initial anti-hypertensive treatment. Scand J Clin Lab Invest. 1976. 36:383–388.

15. Cooper ME. Renal protection and ACE inhibition in microalbuminuric type I and type II diabetic patients. J Hypertens. 1996. 14:S11–S14.

16. Nicholas SB, Kawano Y, Wakino S, Collins AR, Hsueh WA. Expression and function of peroxisome proliferators-activated receptor-r in mesangial cells. Hypertension. 2001. 37:722–727.

17. Buckingham RE, Al-Barazanji KA, Toseland CD, Slaughter M, Connor JC. Peroxisome proliferators-activated receptor-r agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zuker fatty rats. Diabetes. 1998. 47:1326–1334.

20. Khalifah RG, Baynes JW, Hudson BG. Amadorins: novel post-Amadori inhibitors of advanced glycation reactions. Biochem Biophys Res Commun. 1999. 257:251–258.

21. Metz TO, Alderson NL, Thorpe SR, Baynes JW. Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: a novel therapy for treatment of diabetic complications. Arch Biochem Biophys. 2003. 419:41–49.

22. Voziyan PA, Hudson BG. Pyridoxamine as a multifunctional pharmaceutical: targeting pathogenic glycation and oxidative damage. Cell Mol Life Sci. 2005. 62:1671–1681.

23. Khalifah RG, Chen Y, Wassenberg JJ. Post-Amadori AGE inhibition as a therapeutic target for diabetic complications: a rational approach to second-generation Amadorin design. Ann N Y Acad Sci. 2005. 1043:793–806.

24. Kim HY, Kang KS, Yamabe N, Nagai R, Yokozawa T. Protective Effect of Heat-Processed American Ginseng against Diabetic Renal Damage in Rats. J Agric Food Chem. 2007. 55:8491–8497.

26. Yokozawa T, Dong E, Oura H, Kashiwagi H, Nonaka G, Nishioka I. Magnesium lithospermate B suppresses the increase of active oxygen in rats after subtotal nephrectomy. Nephron. 1997. 75:88–93.

27. Kamata K, Iizuka T, Nagai M, Kasuya Y. Endothelium-dependent vasodilator effects of the extract from Salviae Miltiorrhizae radix. A study on the identification of lithospermic acid B in the extracts. Gen Pharmacol. 1993. 24:977–981.

28. Lee GT, Ha H, Jung M, Li H, Hong SW, Cha BS, Lee HC, Cho YD. Delayed treatment with lithospermate B attenuates experimental diabetic renal injury. J Am Soc Nephrol. 2003. 14:709–720.

29. Jung M, Lee HC, Ahn CW, Park W, Choi S, Kim H, Cho D, Lee GT, Li HR. Effective isolation of magnesium lithospermate B and its inhibition of aldose reductase and fibronectin on mesangial cell line. Chem Pharm Bull (Tokyo). 2002. 50:1135–1136.